A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA).: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA). (NCT01734993), a na phase 3 study. The primary outcome is Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs).

2. Clinical Question

The question applies to a selected group who had already completed a substantial period in the preceding WA22762 extension and met the responder definition. It is not a question about starting treatment in an unselected rheumatoid arthritis population, nor does it compare continuation with stopping treatment or with another therapy. The registry lists 11 participants enrolled in this study. Because there is no control group, the posted event counts describe what was recorded among these participants; they cannot by themselves establish how those outcomes would have differed under another treatment or without continued treatment.

3. Trial Design

This was a phase 3, multicenter, open-label, single-group interventional long-term extension study. It evaluated subcutaneous tocilizumab in participants with moderate to severe rheumatoid arthritis. The registry lists Hoffmann-La Roche as sponsor and records the study as completed. The listed start was 2012-10 and primary completion was 2015-09. Enrollment was 11.

Eligibility was restricted to participants from France who had completed the Week 97 visit of the WA22762 long-term extension study and were classified as responders. The responder criterion was improvement in DAS28 of >1.2 points. Participants meeting those conditions continued tocilizumab in this local extension. The study description states a maximum of 156 weeks of subcutaneous treatment, or treatment until subcutaneous tocilizumab became commercially available, whichever occurred first.

There was no random allocation: allocation is listed as not applicable. Masking is listed as none, so the study was open-label. With a single treatment group, there is no concurrent control arm against which to separate treatment-related changes from changes over time, background care, or other influences. The participants had also already completed the earlier extension and met its response criterion, so the enrolled group was selected by prior study participation and response.

The primary outcome was the percentage of participants with adverse events and serious adverse events, assessed from baseline up to approximately 142 weeks. The registry lists secondary outcomes covering disease activity, joint counts, clinical remission, and corticosteroid discontinuation or dose reduction. It does not report a statistical analysis plan, the method for handling missing data, or the approach used to analyze those secondary outcomes. The registry record lists 23 outcome measures, but inferential analyses are not reported.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Safety population

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Safety population included all participants who received at least one dose of study medication.

6. Primary Endpoint

The registry lists the primary outcome as Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs), measured over Baseline up to approximately 142 weeks.

The primary endpoint concerns the percentage of participants who experienced adverse events and serious adverse events from baseline up to approximately 142 weeks. An adverse event was defined broadly as an unfavorable or unintended medical occurrence after study treatment was administered, whether or not it was considered related to treatment. This includes signs, symptoms, diseases, and abnormal laboratory findings temporally associated with treatment. A serious adverse event was defined by specified consequences, including death, life-threatening events, hospitalization or prolonged hospitalization, disability or incapacity, and congenital anomaly or birth defect. The registry definition states that adverse events include serious as well as non-serious events.

This endpoint is used to describe safety events during treatment and follow-up. Counting participants with at least one event gives a participant-level view of whether an event occurred; it is distinct from counting every event occurrence. The posted results identify 11 participants at risk for both the serious-event and other-event categories, with 2 recorded in the serious-event category and 11 in the other-event category. The record labels the outcome as a percentage, but these posted result fields are counts. No confidence interval or inferential comparison is reported in the registry record.

The timeframe is important for interpretation: the primary outcome specifies baseline up to approximately 142 weeks, while the study description allows treatment for a maximum of 156 weeks or until commercial availability, whichever occurred first. The registry record does not explain the relationship between these durations. The endpoint describes observed events in this selected group; it does not establish that treatment caused any particular event.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a single-group study with no masking and no applicable allocation. These design features determine what kinds of statistical conclusions the results can support. A single-group study can report how many participants experienced an event during follow-up. Without a concurrent comparison group, it cannot estimate a treatment contrast using randomized groups. Randomization is generally used to make treatment groups comparable, on average, with respect to both measured and unmeasured factors. That protection is absent when there is only one group.

What does a participant-level event result represent?

The primary outcome is framed as the percentage of participants with adverse events and serious adverse events. A participant-level outcome counts whether a participant experienced an event in the category during the specified period. This differs from counting the total number of event occurrences: one participant can experience more than one event, and an event can be recorded more than once under different terms. The posted results give 11 participants at risk and counts of 2 for serious adverse events and 11 for other adverse events. The registry does not provide enough detail to reconstruct the number of individual event occurrences or the overlap between these categories.

The endpoint definition also matters. An adverse event is an untoward medical occurrence after study treatment, regardless of whether the event was considered related to treatment. Seriousness is defined by the listed medical consequences, such as being life threatening or requiring hospitalization. Seriousness and treatment attribution are separate ideas: an event can meet the seriousness definition without the record establishing that treatment caused it. The posted record does not report causal attribution for the listed terms.

What can an estimate and its uncertainty tell a reader?

In general, an estimate is a summary of the observed data, while a confidence interval describes the statistical uncertainty around an estimate under stated assumptions. A narrow interval indicates greater precision than a wide interval; neither interval width nor the estimate alone resolves sources of bias or establishes causation. No confidence interval is reported for the primary safety outcome in the registry record. Consequently, the event counts can be read descriptively, but their statistical precision is not quantified there.

In general, a p-value evaluates how compatible data are with a specified statistical hypothesis under a particular model. It is not a measure of clinical importance and does not establish causality. No p-value or inferential analysis for the primary safety outcome is reported in the registry record. The record also does not report a statistical analysis plan, so the intended hypothesis tests, if any, cannot be identified.

Why does a control group matter?

A comparison asks how outcomes differ between groups under defined conditions. In a randomized comparison, the analysis can estimate a contrast between assigned strategies, subject to adherence, missing-data, and other assumptions. Here, there is no control arm. Comparing the observed participants with an external expectation would require additional information and assumptions not reported in the registry record. The posted event counts therefore describe the enrolled group rather than a treatment effect.

Selection also affects interpretation. Participants had to complete the Week 97 visit in a prior extension and meet the responder criterion of improvement in DAS28 of >1.2 points. Conditioning enrollment on prior participation and response means this study does not directly represent all people with moderate to severe rheumatoid arthritis. The single-group design and selected cohort are features of the evidence, not statistical defects that can be corrected simply by calculating a different summary.

How should planning calculations be understood?

In general, a sample-size calculation uses assumptions about the effect to detect, the significance level, allocation, and statistical model. The planning illustrations associated with this record use a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the stated effect to detect is a fraction of the observed effect. For time-to-event calculations, the illustration is based on a total number of events, while other calculations are expressed as participants per arm. Such calculations are planning illustrations, not evidence that the study had a particular probability of detecting an effect, and they are not the observed power of this trial.

Those assumptions do not describe the registered single-group design, which has no two-arm allocation. The registry record does not report the trial’s own sample-size justification or a planned comparator. Because the primary endpoint is a safety count and no comparative effect estimate is reported, the planning assumptions should not be treated as the design basis for this extension or as a way to infer a treatment effect.

Finally, statistical methods for repeated disease-activity measurements, time to corticosteroid discontinuation, and other secondary outcomes depend on how observations over time and missing values are handled. The registry lists these outcomes but does not report the models, estimands, confidence intervals, or missing-data methods. Any more specific account of those analyses would therefore go beyond what the registry record documents.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists multiple secondary outcomes, including changes in DAS28-ESR and SDAI, changes in tender and swollen joint counts, clinical remission, and several corticosteroid-related outcomes. When many outcomes are examined, the chance of obtaining at least one apparently notable result can increase if each is tested separately. General approaches to this issue include prespecifying a hierarchy, adjusting significance thresholds, or treating analyses as exploratory. The registry record does not report whether any such multiplicity strategy was planned or used. It also does not identify a hierarchy among the secondary outcomes.

Missing-data handling is not reported in the registry record. This matters because participants may have different amounts of follow-up, and incomplete outcome information can affect both participant-level event summaries and longitudinal measures. The study description permits treatment to end when subcutaneous tocilizumab becomes commercially available or after a maximum of 156 weeks, whichever occurs first; the primary safety timeframe is baseline up to approximately 142 weeks. The record does not explain how follow-up ending for different reasons was handled in the analysis.

The primary outcome identifies the safety population, but the registry does not describe the population definitions used for secondary outcomes or how participants with incomplete observations were included. It lists 23 outcome measures, while inferential analyses are not reported. The analysis plan, interim analyses, and rules for handling withdrawals or missing assessments are not reported in the registry record. These omissions prevent a fuller assessment of how outcome selection, missingness, and analysis decisions may have influenced the reported results.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: osteonecrosis (9.1%), inflammatory pseudotumour (9.1%), extremity necrosis (9.1%).

The safety result records 2 participants with serious adverse events among 11 at risk, and 11 participants with other adverse events among 11 at risk. The endpoint definition says that adverse events include serious adverse events as well as non-serious adverse events. Therefore, the two categories are not necessarily exclusive, and their counts should not be added together to estimate the number of participants with any event.

The registry lists osteonecrosis, inflammatory pseudotumour, and extremity necrosis as serious adverse event terms, each at 9.1%. The record does not provide enough detail to treat these terms as a complete account of all events, nor does it report whether any were judged related to treatment. A serious adverse event is categorized by its seriousness criteria; that label alone does not establish cause. The deaths field is not reported in the registry record, which is different from a reported count of zero.

These figures describe the observed safety experience in a small, selected, single-group cohort over the registry’s stated timeframe. They do not provide a comparison with another treatment and do not establish what would have occurred in the absence of tocilizumab. No confidence interval is reported, so the precision of the event frequencies is not quantified.

12. What the Result Does, and Does Not, Mean

The results establish that the registry recorded adverse events during this extension study: 11 participants were at risk in the other-event category and 11 were recorded with such events; 11 were at risk in the serious-event category and 2 were recorded with serious adverse events. The serious-event terms listed in the record were osteonecrosis, inflammatory pseudotumour, and extremity necrosis, each reported at 9.1%. These are descriptive findings for this study’s enrolled group and observation period.

They do not establish that tocilizumab caused the recorded events. The adverse-event definition includes events regardless of whether a causal relationship with treatment was considered. The record does not give causal assessments for the listed terms. Nor do the findings establish that treatment prevented or improved rheumatoid arthritis outcomes: the listed secondary outcomes do not have inferential results reported in the registry record.

The study also cannot show how safety or disease activity would compare with another treatment or with no continued treatment. It was open-label and single-group, with no concurrent comparator. The enrolled participants were not an unselected rheumatoid arthritis population; they were from France, had completed a prior extension visit, and met the specified responder criterion. Generalizing the results beyond participants with that history requires caution.

The event counts are not a precise estimate of risk for a broader population. The registry does not report a confidence interval for the primary endpoint, and the small cohort means the descriptive results should be interpreted in context rather than as a stable estimate. The record gives no basis for weighing the benefits and harms of treatment for an individual. Its contribution is narrower: it documents safety observations in a selected long-term extension cohort, while leaving comparative and causal questions unanswered.

13. Why This Trial Matters Statistically

This study illustrates a common statistical challenge in long-term extensions: the available evidence can describe treatment experience over time, but the design may not support a comparative conclusion. Participants continued treatment after completing an earlier extension and meeting a response criterion. That makes the cohort relevant to the experience of selected continuing participants, while also limiting its relevance to people who would not reach that point or meet that criterion.

The registry record distinguishes an adverse event from a serious adverse event by definition, but the participant counts should not be treated as separate, additive groups. The serious category is included within the broader adverse-event definition. Understanding this nesting is essential when reading event summaries: combining overlapping categories can misstate how many people experienced any event.

The record also shows why endpoint labels and analysis results are not interchangeable. It lists a primary safety outcome and secondary disease-activity and corticosteroid outcomes, but does not report inferential analyses. Outcome names alone cannot show the size, direction, or precision of any treatment-related change. Likewise, listing serious adverse event terms does not establish treatment attribution.

Statistically, the study’s value lies in documenting observations within its stated population and follow-up, not in supplying a randomized contrast. Its limitations are particularly visible in the absence of a control group, the selected responder cohort, and the lack of reported uncertainty estimates or analysis methods. Recognizing those boundaries helps readers use the record for what it can support—description of recorded safety events—without extending its results to comparative efficacy or causal claims.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The main limitation is the single-group design. With no concurrent control, the study cannot separate the experience during continued tocilizumab treatment from what might have happened under another strategy. Open-label conduct also means treatment was not masked, although the registry does not describe how this affected event reporting or assessment.

The enrolled population was small, with 11 participants, and selected by prior study participation and response. Participants had to be from France, complete the Week 97 visit of the earlier extension, and meet the responder definition of DAS28 improvement of >1.2 points. The findings therefore have limited direct applicability to people who were not eligible for that extension or did not meet those conditions.

The registry lists the safety population and the primary endpoint timeframe of baseline up to approximately 142 weeks. The study description separately states a maximum treatment duration of 156 weeks or until subcutaneous tocilizumab became commercially available, whichever occurred first. The record does not explain how these timeframes relate in the analysis, or how differing follow-up durations were addressed.

Uncertainty and analysis details are not reported. The registry record gives no confidence interval for the primary safety outcome, no inferential analyses, no statistical analysis plan, and no missing-data methods. It also does not report treatment attribution for the serious adverse event terms. The deaths field is not reported in the registry record. These gaps limit assessment of precision, completeness, and the basis for any conclusions beyond the observed counts.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: A Long-Term Extension Study of WA22762 to Evaluate Safety and Efficacy of Subcutaneous Tocilizumab in Participants With Moderate to Severe Rheumatoid Arthritis (RA). — NCT01734993.
• Registry record last updated 2016-11-28; status last verified 2016-10.
• Results first posted 2016-11-28.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT01734993 is a completed phase 3, open-label, single-group long-term extension study sponsored by Hoffmann-La Roche. It enrolled 11 participants with moderate to severe rheumatoid arthritis from France who had completed the Week 97 visit of the WA22762 extension and met the stated responder criterion. Participants continued subcutaneous tocilizumab, for a maximum of 156 weeks or until commercial availability, whichever occurred first. The listed start was 2012-10 and primary completion was 2015-09.

The primary outcome was the percentage of participants with adverse events and serious adverse events from baseline up to approximately 142 weeks. The posted results record 2 participants with serious adverse events among 11 at risk and 11 participants with other adverse events among 11 at risk. Three serious adverse event terms are listed, each at 9.1%. Secondary outcomes include disease-activity, joint-count, remission, and corticosteroid measures. Inferential analyses, confidence intervals, missing-data methods, and a statistical analysis plan are not reported in the registry record. The single-group design supports descriptive interpretation, not a randomized treatment comparison.